PHASE I STUDY OF TRIAPINE IN COMBINATION WITH DOXORUBICIN IN REFRACTORY TUMORS

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. (Clinical trial summary from the National Cancer Institute's PDQ database) Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Triapine (3-AP) may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth and may help doxorubicin kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side-effects and best dose of triapine and doxorubicin in treating patients with metastatic or refractory solid tumors. Patients will receive an infusion of doxorubicin on Day 1. They will also receive a 2-hour infusion of triapine on Days 1-4. Treatment may be repeated every 3 weeks for as long as benefit is shown. Patients will be evaluated periodically.